{"id":571898,"date":"2025-12-24T00:00:00","date_gmt":"2025-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrop0008-2025-biopharma-dry-eye-current-treatment-current-treatment-physician-insights-dry-eye-disease-eu3\/"},"modified":"2026-05-02T23:14:27","modified_gmt":"2026-05-02T23:14:27","slug":"cutrop0008-2025-biopharma-dry-eye-current-treatment-current-treatment-physician-insights-dry-eye-disease-eu3","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrop0008-2025-biopharma-dry-eye-current-treatment-current-treatment-physician-insights-dry-eye-disease-eu3\/","title":{"rendered":"Dry Eye &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Dry Eye Disease (EU3)"},"content":{"rendered":"<p>Dry eye disease (<abbr title=\"dry eye disease\">DED<\/abbr>) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. In Europe, <abbr title=\"dry eye disease\">DED<\/abbr> has traditionally been managed with over-the-counter artificial tears to maintain ocular lubrication and off-label ophthalmic corticosteroids for rapid symptom relief, as well as nonpharmacological interventions such as device-assisted therapies, intense pulse light laser treatment, and surgical procedures (e.g., punctal occlusion). Apart from Rayner\u2019s ilube in the United Kingdom, Santen\u2019s Ikervis has been the only approved treatment for <abbr title=\"dry eye disease\">DED<\/abbr> in Europe. However, due to its narrow indication\u2014severe keratitis in adult <abbr title=\"dry eye disease\">DED<\/abbr> patients unresponsive to tear substitutes\u2014Ikervis is reserved for eligible patients. In this report, we discuss European ophthalmologists\u2019 prescribing practices and the key factors influencing their choice of therapy for <abbr title=\"dry eye disease\">DED<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the drivers and constraints influencing physicians\u2019 treatment decisions for <abbr title=\"dry eye disease\">DED<\/abbr>?<\/li>\n<li>How are <abbr title=\"dry eye disease\">DED<\/abbr> patients being managed across different lines of therapy?<\/li>\n<li>What patient share does Ikervis capture in <abbr title=\"dry eye disease\">DED<\/abbr>?<\/li>\n<li>How are nonpharmacological approaches integrated in the treatment algorithm for <abbr title=\"dry eye disease\">DED<\/abbr> in each of the EU3 countries?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Italy, Spain, United Kingdom<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Through survey data from EU3 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand&#8217;s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-571898","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-dry-eye","biopharma-therapy-areas-ophthalmology","biopharma-product-current-treatment","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571898\/revisions"}],"predecessor-version":[{"id":572130,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571898\/revisions\/572130"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=571898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}